Overview

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

Status:
COMPLETED

Trial end date:
2025-01-15

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine. Another secondary objective is to characterize the pharmacokinetics of ZYPREXA. The planned duration of the study for each participant is 19 weeks.

Phase:

PHASE1

Details

Lead Sponsor:

Teva Branded Pharmaceutical Products R&D, Inc.

Treatments:

Olanzapine